Free Trial

OPKO Health (OPK) Competitors

OPKO Health logo
$1.30 -0.03 (-2.26%)
Closing price 04:00 PM Eastern
Extended Trading
$1.32 +0.02 (+1.54%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPK vs. BCRX, LGND, FOLD, MNKD, CLDX, DVAX, INVA, NVAX, GERN, and RGLS

Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.

OPKO Health vs.

OPKO Health (NASDAQ:OPK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

OPKO Health has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

OPKO Health has a net margin of -18.65% compared to BioCryst Pharmaceuticals' net margin of -30.01%. BioCryst Pharmaceuticals' return on equity of 0.00% beat OPKO Health's return on equity.

Company Net Margins Return on Equity Return on Assets
OPKO Health-18.65% -9.76% -6.46%
BioCryst Pharmaceuticals -30.01%N/A -24.06%

OPKO Health received 15 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. However, 67.12% of users gave BioCryst Pharmaceuticals an outperform vote while only 65.60% of users gave OPKO Health an outperform vote.

CompanyUnderperformOutperform
OPKO HealthOutperform Votes
513
65.60%
Underperform Votes
269
34.40%
BioCryst PharmaceuticalsOutperform Votes
498
67.12%
Underperform Votes
244
32.88%

OPKO Health has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OPKO Health$689.41M1.50-$188.86M-$0.07-18.57
BioCryst Pharmaceuticals$503.49M4.19-$226.54M-$0.26-38.73

In the previous week, BioCryst Pharmaceuticals had 5 more articles in the media than OPKO Health. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 4 mentions for OPKO Health. BioCryst Pharmaceuticals' average media sentiment score of 1.07 beat OPKO Health's score of 0.86 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OPKO Health
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioCryst Pharmaceuticals
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

OPKO Health presently has a consensus target price of $2.75, indicating a potential upside of 111.54%. BioCryst Pharmaceuticals has a consensus target price of $16.56, indicating a potential upside of 64.40%. Given OPKO Health's higher probable upside, equities analysts plainly believe OPKO Health is more favorable than BioCryst Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OPKO Health
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
BioCryst Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

OPKO Health beats BioCryst Pharmaceuticals on 10 of the 18 factors compared between the two stocks.

Get OPKO Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPK vs. The Competition

MetricOPKO HealthPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.03B$6.48B$5.35B$8.38B
Dividend YieldN/A2.66%5.22%4.10%
P/E Ratio-6.848.9226.8419.71
Price / Sales1.50250.95391.39116.98
Price / CashN/A65.8538.2534.62
Price / Book0.726.466.794.50
Net Income-$188.86M$143.98M$3.23B$248.18M
7 Day Performance3.17%3.04%4.07%1.14%
1 Month Performance-5.11%7.44%12.52%15.20%
1 Year PerformanceN/A-2.46%16.83%6.56%

OPKO Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPK
OPKO Health
4.4084 of 5 stars
$1.30
-2.3%
$2.75
+111.5%
+0.8%$1.03B$689.41M-6.844,200
BCRX
BioCryst Pharmaceuticals
4.6145 of 5 stars
$10.34
+3.7%
$16.56
+60.1%
+68.5%$2.16B$503.49M-16.95530Positive News
LGND
Ligand Pharmaceuticals
4.3924 of 5 stars
$106.38
+1.8%
$146.14
+37.4%
+21.1%$2.05B$181.49M42.3880
FOLD
Amicus Therapeutics
4.0095 of 5 stars
$6.21
+3.8%
$16.22
+161.2%
-32.4%$1.91B$543.14M-34.50480News Coverage
Positive News
High Trading Volume
MNKD
MannKind
2.7862 of 5 stars
$4.81
+5.5%
$10.00
+107.9%
-7.2%$1.46B$297.60M68.71400
CLDX
Celldex Therapeutics
1.7838 of 5 stars
$20.18
+10.1%
$53.90
+167.1%
-45.7%$1.34B$7.02M-7.85150Positive News
Gap Down
DVAX
Dynavax Technologies
4.2645 of 5 stars
$9.85
+4.7%
$24.00
+143.7%
-8.5%$1.18B$294.62M54.72350Positive News
High Trading Volume
INVA
Innoviva
4.3431 of 5 stars
$18.61
+0.3%
$55.00
+195.5%
+16.4%$1.17B$369.84M26.97100News Coverage
Positive News
NVAX
Novavax
3.7453 of 5 stars
$6.34
+6.0%
$17.71
+179.4%
-48.1%$1.02B$682.16M-2.811,990
GERN
Geron
4.1106 of 5 stars
$1.28
+8.5%
$5.06
+295.5%
-62.7%$815.26M$116.29M-4.0070Positive News
RGLS
Regulus Therapeutics
1.3238 of 5 stars
$7.87
flat
$8.50
+8.0%
+295.5%$521.33MN/A-7.3630Analyst Forecast

Related Companies and Tools


This page (NASDAQ:OPK) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners